Robert E Hutchison
Overview
Explore the profile of Robert E Hutchison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dutta A, Nath D, Yang Y, Le B, Rahman M, Faughnan P, et al.
Leukemia
. 2021 Nov;
36(3):746-759.
PMID: 34741118
Myelofibrosis (MF) is the deadliest form of myeloproliferative neoplasm (MPN). The JAK inhibitor Ruxolitinib can reduce constitutional symptoms but it does not substantially improve bone marrow fibrosis. Pim1 expression is...
2.
Horton T, Sheehan A, Lopez-Terrada D, Hutchison R, Narendra S, Wu M, et al.
Lymphoma
. 2019 Aug;
2012.
PMID: 31406604
Constitutively active nuclear factor-κB (NF-κB) is integral to the survival of Hodgkin/Reed-Sternberg cells (H/RS) in Hodgkin Lymphoma (HL). To investigate NF-κB pathway proteins in pediatric HL, we utilized a tissue...
3.
Cassol C, Hod-Dvorai R, Hubbell C, Aggarwal V, Sinha S, Gentile T, et al.
Am J Transplant
. 2018 Sep;
19(3):956-957.
PMID: 30222902
No abstract available.
4.
Hudson S, Wang D, Middleton F, Nevaldine B, Naous R, Hutchison R
Pediatr Blood Cancer
. 2018 Apr;
65(8):e27094.
PMID: 29697184
Background: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) shows 60-70% event free survival with standard treatments. Targeted therapies are being tested for increased benefit and/or reduced toxicity, but...
5.
Aldrink J, Appel B, Kaplan J, Hutchison R, Schwartz C, Kelly K, et al.
J Pediatr Hematol Oncol
. 2018 Feb;
40(3):246-247.
PMID: 29401099
No abstract available.
6.
Welch J, Schwartz C, Higman M, Chen L, Buxton A, Kanakry J, et al.
Blood Adv
. 2018 Jan;
1(11):681-684.
PMID: 29296710
Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good...
7.
Untanu R, Back J, Appel B, Pei Q, Chen L, Buxton A, et al.
Pediatr Blood Cancer
. 2017 Aug;
65(1).
PMID: 28802087
Background: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. Procedure: One...
8.
Dutta A, Hutchison R, Mohi G
Blood
. 2017 Jun;
130(7):920-932.
PMID: 28637665
Myelofibrosis (MF) is a devastating blood disorder. The mutation has been detected in ∼50% cases of MF. Elevated expression of high-mobility group AT hook 2 (HMGA2) has also been frequently...
9.
Dutta A, Yan D, Hutchison R, Mohi G
Br J Haematol
. 2016 Dec;
180(6):911-915.
PMID: 28025836
No abstract available.
10.
Schwartz C, Chen L, McCarten K, Wolden S, Constine L, Hutchison R, et al.
Pediatr Blood Cancer
. 2016 Oct;
64(4).
PMID: 27786406
Background: Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after two to three cycles of chemotherapy may inform therapeutic...